Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
TQB2223
i
Other names:
TQB2223
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Sino Biopharm
Drug class:
LAG-3 inhibitor
Related drugs:
‹
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
IBI110 (2)
MK-4280 (2)
REGN3767 (2)
FS118 (1)
BMS-986016 (1)
ABL501 (0)
CB213 (0)
EMB-02 (0)
GB266 (0)
GLS-012 (0)
HLX26 (0)
IBI-323 (0)
INCA32459 (0)
LBL-007 (0)
SHR-1802 (0)
Sym022 (0)
TNRX-257 (0)
ZGGS15 (0)
XmAb22841 (0)
TSR-033 (0)
MK-4280A (0)
LAG525 (0)
BI 754111 (0)
RG6139 (0)
INCAGN2385 (0)
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
IBI110 (2)
MK-4280 (2)
REGN3767 (2)
FS118 (1)
BMS-986016 (1)
ABL501 (0)
CB213 (0)
EMB-02 (0)
GB266 (0)
GLS-012 (0)
HLX26 (0)
IBI-323 (0)
INCA32459 (0)
LBL-007 (0)
SHR-1802 (0)
Sym022 (0)
TNRX-257 (0)
ZGGS15 (0)
XmAb22841 (0)
TSR-033 (0)
MK-4280A (0)
LAG525 (0)
BI 754111 (0)
RG6139 (0)
INCAGN2385 (0)
›
Associations
News
Trials
Filter by
Latest
8ms
Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma. (clinicaltrials.gov)
P1, N=34, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
8 months ago
New P1 trial • Metastases
|
Anniko (penpulimab) • TQB2223
over1year
TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers (clinicaltrials.gov)
P1, N=92, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
over 1 year ago
New P1 trial • Combination therapy • Metastases
|
LAG3 (Lymphocyte Activating 3)
|
Anniko (penpulimab) • TQB2223
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login